Short Bowel Syndrome Market Higher Growth Rate & Forecast 2020 – 2030

Published On : 11/22/2021

Description:

Short Bowel Syndrome Market: Introduction

According to the report, the global short bowel syndrome market was valued at US$ 728.3 Mn in 2020 and is projected to expand at a CAGR of 15.9% from 2021 to 2031. Incentives and R&D grants for manufacturers of orphan drugs, rise in prevalence of SBS, and favorable reimbursement scenario are anticipated to propel the global short bowel syndrome market. Japan is likely to be a highly lucrative market for short bowel syndrome drugs from 2021 to 2031. The market in the country is projected to expand at a high CAGR during the forecast period.

Increase in Demand for SBS Drugs Due to High Cost of Parenteral Nutrition to Drive Market

Most of the short bowel syndrome patients are on parenteral nutrition initially until the patients’ intestine has adopted and hemostasis is being maintained. The cost of parenteral nutrition varies from patient to patient, and ranges between US$ 150,000 and US$ 586,000 per year. The high cost of parenteral nutrition increases demand for short bowel syndrome drugs, which have shown the ability to reduce patient’s dependence on parenteral nutrition during the clinical trials.

Request Brochure of Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=13346

For instance, apraglutide has the potential to enable patients to minimize the burden from parenteral support by increasing intestinal absorption of fluids, calories, and nutrients. Apraglutide has completed phase 2 studies and is currently being evaluated in a pivotal phase 3 clinical trial. Based on preclinical and clinical data to date, apraglutide has the potential to facilitate the treatment of SBS-IF by establishing less frequent dosing and improving outcomes in a clinically meaningful fashion to address the needs of patients across the anatomical spectrum that characterizes the disease.

Request for Analysis of COVID19 Impact on Short Bowel Syndrome Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=13346

Glucagon-like Peptide-2 (GLP-2) to Dominate Global Market

In terms of product, the global short bowel syndrome market has been classified into glucagon-like peptide-2 (GLP-2), growth hormone, glutamine, and others. The glucagon-like peptide-2 segment dominated the global short bowel syndrome market in 2020, and the trend is projected to continue during the forecast period.  The segment’s dominance can be attributed to increase in sales of Gattex/Revestive in the U.S. and Europe. Additionally, it is the only approved drug for the treatment of SBS across the globe.

Retail Pharmacies to be Highly Lucrative Distribution Channel

Based on distribution channel, the global short bowel syndrome market has been divided into hospital pharmacies, retail pharmacies, and online sales. The retail pharmacies segment dominated the global short bowel syndrome market, and the trend is anticipated to continue during the forecast period. The segment is expected to dominate the global short bowel syndrome market due to higher sales of drugs through retail pharmacies in developed countries including the U.S., Europe, and Canada.

Buy Short Bowel Syndrome Market Report – https://www.transparencymarketresearch.com/checkout.php?rep_id=13346&ltype=S

Competition Landscape

Key players in the global short bowel syndrome market include Takeda Pharmaceutical Company Limited, Merck KGaA, Zealand Pharma A/S, OxThera, VectivBio AG, 9 Meters Biopharma, Inc., Nutrinia Ltd., Hanmi Pharm.Co., Ltd., and Pharmascience, Inc.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals. Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information, we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact Us

Mr. Rohit Bhisey

Transparency Market Research

USA – Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Blog: https://tmrblog.com/

Follow Us: Twitter | LinkedIn

Press Release Source: https://www.transparencymarketresearch.com/pressrelease/short-bowel-syndrome-market.htm

Uma Rajagopal

Uma Rajagopal has been managing the posting of content for multiple platforms since 2021, including Global Banking & Finance Review, Asset Digest, Biz Dispatch, Blockchain Tribune, Business Express, Brands Journal, Companies Digest, Economy Standard, Entrepreneur Tribune, Finance Digest, Fintech Herald, Global Islamic Finance Magazine, International Releases, Online World News, Luxury Adviser, Palmbay Herald, Startup Observer, Technology Dispatch, Trading Herald, and Wealth Tribune. Her role ensures that content is published accurately and efficiently across these diverse publications.